137 related articles for article (PubMed ID: 23059870)
21. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
22. Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs.
Hogge GS; Burkholder JK; Culp J; Albertini MR; Dubielzig RR; Yang NS; MacEwen EG
Cancer Gene Ther; 1999; 6(1):26-36. PubMed ID: 10078961
[TBL] [Abstract][Full Text] [Related]
23. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
[TBL] [Abstract][Full Text] [Related]
24. Canine oral melanoma.
Bergman PJ
Clin Tech Small Anim Pract; 2007 May; 22(2):55-60. PubMed ID: 17591290
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
[TBL] [Abstract][Full Text] [Related]
26. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
O'Day SJ; Boasberg PD; Piro L; Kristedja TS; Wang HJ; Martin M; Deck R; Ames P; Shinn K; Kim H; Fournier P; Gammon G
Clin Cancer Res; 2002 Sep; 8(9):2775-81. PubMed ID: 12231516
[TBL] [Abstract][Full Text] [Related]
27. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial.
Bergman PJ; McKnight J; Novosad A; Charney S; Farrelly J; Craft D; Wulderk M; Jeffers Y; Sadelain M; Hohenhaus AE; Segal N; Gregor P; Engelhorn M; Riviere I; Houghton AN; Wolchok JD
Clin Cancer Res; 2003 Apr; 9(4):1284-90. PubMed ID: 12684396
[TBL] [Abstract][Full Text] [Related]
28. Enhanced antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte-macrophage colony-stimulating factor gene transfer.
Cao X; Huang X; Ju DW; Zhang W; Hamada H; Wang J
Cancer Gene Ther; 2000 Feb; 7(2):177-86. PubMed ID: 10770625
[TBL] [Abstract][Full Text] [Related]
29. A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma.
Treggiari E; Grant JP; North SM
J Vet Med Sci; 2016 Jun; 78(5):845-50. PubMed ID: 26781703
[TBL] [Abstract][Full Text] [Related]
30. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs.
Manley CA; Leibman NF; Wolchok JD; Rivière IC; Bartido S; Craft DM; Bergman PJ
J Vet Intern Med; 2011; 25(1):94-9. PubMed ID: 21143299
[TBL] [Abstract][Full Text] [Related]
31. Individualized synthetic peptide vaccines with GM-CSF in locally advanced melanoma patients.
Atzpodien J; Fluck M; Reitz M
Cancer Biother Radiopharm; 2004 Dec; 19(6):758-63. PubMed ID: 15665624
[TBL] [Abstract][Full Text] [Related]
32. Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma.
von Euler H; Sadeghi A; Carlsson B; Rivera P; Loskog A; Segall T; Korsgren O; Tötterman TH
J Immunother; 2008 May; 31(4):377-84. PubMed ID: 18391758
[TBL] [Abstract][Full Text] [Related]
33. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center.
Bergman PJ; Camps-Palau MA; McKnight JA; Leibman NF; Craft DM; Leung C; Liao J; Riviere I; Sadelain M; Hohenhaus AE; Gregor P; Houghton AN; Perales MA; Wolchok JD
Vaccine; 2006 May; 24(21):4582-5. PubMed ID: 16188351
[TBL] [Abstract][Full Text] [Related]
34. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
35. Malignant melanoma in 63 dogs (2001-2011): the effect of carboplatin chemotherapy on survival.
Brockley LK; Cooper MA; Bennett PF
N Z Vet J; 2013 Jan; 61(1):25-31. PubMed ID: 22913610
[TBL] [Abstract][Full Text] [Related]
36. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M
Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699
[TBL] [Abstract][Full Text] [Related]
37. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma.
Alexander AN; Huelsmeyer MK; Mitzey A; Dubielzig RR; Kurzman ID; Macewen EG; Vail DM
Cancer Immunol Immunother; 2006 Apr; 55(4):433-42. PubMed ID: 15965647
[TBL] [Abstract][Full Text] [Related]
38. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
; Celis E
Cancer; 2007 Jul; 110(1):203-14. PubMed ID: 17541944
[TBL] [Abstract][Full Text] [Related]
39. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine.
Milner RJ; Salute M; Crawford C; Abbot JR; Farese J
Vet Immunol Immunopathol; 2006 Dec; 114(3-4):273-84. PubMed ID: 17027091
[TBL] [Abstract][Full Text] [Related]
40. [tag7 Gene and gene therapy of cancer].
Kiselev SL; Larin SS; Gnuchev NV; Georgiev GP
Genetika; 2000 Nov; 36(11):1431-5. PubMed ID: 11094759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
